Biotechs face a core communication challenge. How, in an industry that can spawn hundreds of startups every year, can you connect with the talent and investors who are integral to your prospects?

In the sea of proteins in the body, drug researchers are navigating to the ones that cause disease. Of the 20,000 proteins that make up the human proteome, 5,000 are known to play a role in disease.

Belharra Therapeutics is finally ready to rise out of stealth with $130 million in capital and Genentech caught up in the wave with a multiple-year collaboration. The newly-emerged biotech is off to a ...

--Next-generation chemoproteomics company launched by Versant Ventures’ Inception Discovery Engine with ability to target any binding site, on any protein, in any cell type-- Belharra’s integrated ...

SAN MATEO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, today announced ...

Dr. Buchanan will helm Belharra’s research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches its ...

Belharra Therapeutics has announced that it has entered a strategic partnership with global powerhouse Sanofi to spur the development of small molecule therapies for immunological diseases. Under the ...

Europe is not normally associated with big waves but this monster is up there with the biggest in the world Among those who made the trip is Shane Dorian who travelled from Hawaii and caught just two ...

SAN MATEO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Belharra Therapeutics, Inc. today emerged from stealth mode with a novel photoaffinity-based chemoproteomics platform capable of identifying ...

–Next-generation chemoproteomics company launched by Versant Ventures’ Inception Discovery Engine with ability to target any binding site, on any protein, in any cell type– SAN MATEO, Calif. & SAN ...